COVID-19 Treatments TRACKER

Federally-funded and private sector researchers are working diligently to find effective treatments for COVID-19, whether through developing novel therapeutics or repurposing previously-approved drugs. Download this infographic to learn more about COVID-19 treatments that have been approved for use or are in development





Traditional vaccines introduce a weakened form of a virus that will train the immune system to recognize and combat viral pathogens. Two of the leading COVID-19 vaccine candidates are RNA-based, a revolutionary strategy that uses our body’s own genetic machinery. Following collection of ‘clear and compelling’ efficacy and safety data from at least one Phase III clinical trial, a vaccine manufacturer may file for Emergency Use Authorization (EUA). But what does the clinical trial process look like? How might an EUA effect this process? How has the introduction of boosters impacted approval and reccomendations?

Download this infographic to learn more.

The science of STEM cells

Research involving stem cells is an integral part of the U.S. biomedical research landscape, aiding the development of life-saving therapeutics, improving our understanding of human development and countless diseases, and establishing a new platform for revolutionary cell therapies. But what are stem cells and how do they work? How do stem cells differ from fetal tissue?

Download this infographic to learn more.

To learn more about stem cell research, click here.



Understanding RNAi

What is RNAi? How does it work? RNAi is a promising tool for disease intervention. Scientists have learned how to manipulate this naturally occurring process, designing synthetic interfering RNAs that can silence specific genes that cause disease. RNAi may be useful for treating cancer, autoimmune diseases, genetic disorders, and viral infections--potentially every human disease caused by abnormal gene activity can be targeted by RNAi. 

Download this infographic to learn more.




Research Innovation's Legislative Legacy

The Bayh-Dole Act (1980) enabled the decentralization of patent management. Academic institutions, nonprofits, and businesses now had ownership of any intellectual property (IP) that arose in part from federal funding. These entities could then license that IP to industry, enabling commercial development. This new method of technology transfer incentivized researchers to pursue commercialization of their innovations

Download this infographic on technology transfer.





This graphic helps us answer the question "What is the objective?", when we hear about a certain treatment or vaccine candidate. Additionally, COVID-19 has catalyzed a re-structuring of the ways in which treatments and vaccines make it from the laboratory to the doctor's office. Here, modifications to the research and clinical development process are also shown. This graphic helps us answer the question "What is the process?", when we ask what new treatments and vaccines must undergo in order to be fast-tracked to the public. Together, these representations provide an overview of the many approaches being utilized by the research community to combat the current public health threat and deliver safe interventions to the public as quickly as possible. 

Download this infographic of the R&D process for COVID-19 vaccine development.

R&D Pipeline and Tech Transfer

There are five main phases in research and development (R&D): basic research, applied research, clinical trials, regulatory review, and production & distribution. Academic and independent research institutions, private companies, and the federal government play unique and complementary roles in the R&D ecosystem. Learn more drug development and how research takes treatments from bench to bedside.


Download this Biomedical Research and Development Pipeline infographic.

Congressional Appropriations Process

The appropriations process is an annual event. Congress is tasked with producing a budget resolution and 12 appropriations bills for each federal fiscal year, which begins on October 1. Other funding legislation, such as emergency funding in response to emergencies ;ike COVID-19 frequently occurs outside of the standard process.


Click here to learn more about the appropriations process.